Compartir
array:23 [ "pii" => "S1576988724000219" "issn" => "15769887" "doi" => "10.1016/j.vacun.2024.02.006" "estado" => "S300" "fechaPublicacion" => "2024-04-01" "aid" => "346" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2024" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Vacunas. 2024;25:228-32" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S1576988723000705" "issn" => "15769887" "doi" => "10.1016/j.vacun.2023.08.004" "estado" => "S300" "fechaPublicacion" => "2024-04-01" "aid" => "317" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Vacunas. 2024;25:233-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "The co-infection of SARS-CoV-2 with atypical bacterial respiratory infections: A mini review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "233" "paginaFinal" => "238" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La coinfección de SARS-CoV-2 con infecciones respiratorias bacterianas atípicas: Una mini revision" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Fateme Taheri, Soheil Vesal, Parnian Goudarzi, Zahra Sahafnejad, Amin Khoshbayan" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Fateme" "apellidos" => "Taheri" ] 1 => array:2 [ "nombre" => "Soheil" "apellidos" => "Vesal" ] 2 => array:2 [ "nombre" => "Parnian" "apellidos" => "Goudarzi" ] 3 => array:2 [ "nombre" => "Zahra" "apellidos" => "Sahafnejad" ] 4 => array:2 [ "nombre" => "Amin" "apellidos" => "Khoshbayan" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988723000705?idApp=UINPBA00004N" "url" => "/15769887/0000002500000002/v2_202405080710/S1576988723000705/v2_202405080710/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1576988724000189" "issn" => "15769887" "doi" => "10.1016/j.vacun.2024.02.004" "estado" => "S300" "fechaPublicacion" => "2024-04-01" "aid" => "344" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Vacunas. 2024;25:224-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Vacunación COVID-19 y búsquedas web sobre salud mental: un estudio infodemiológico mundial" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "224" "paginaFinal" => "227" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "COVID-19 vaccination and web search on mental health: A worldwide infodemiological study" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juan Antonio Becerra-García, Sara Barbeito, Teresa Sánchez-Gutiérrez" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Juan Antonio" "apellidos" => "Becerra-García" ] 1 => array:2 [ "nombre" => "Sara" "apellidos" => "Barbeito" ] 2 => array:2 [ "nombre" => "Teresa" "apellidos" => "Sánchez-Gutiérrez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S244514602400027X" "doi" => "10.1016/j.vacune.2024.04.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S244514602400027X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988724000189?idApp=UINPBA00004N" "url" => "/15769887/0000002500000002/v2_202405080710/S1576988724000189/v2_202405080710/es/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Analysis of the level of protective serum antibody after third dose of different COVID-19 vaccines" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "228" "paginaFinal" => "232" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Atena Mansouri, Mitra Rafiee, Seyed-Alireza Esmaeili, Saboura Nikpour, Alireza Fereidouni, Mohammad Fereidouni" "autores" => array:6 [ 0 => array:4 [ "nombre" => "Atena" "apellidos" => "Mansouri" "email" => array:1 [ 0 => "mansouri_atena@bums.ac.ir" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "af0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cr0005" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "fn0005" ] ] ] 1 => array:3 [ "nombre" => "Mitra" "apellidos" => "Rafiee" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "af0005" ] ] ] 2 => array:3 [ "nombre" => "Seyed-Alireza" "apellidos" => "Esmaeili" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "af0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "af0015" ] ] ] 3 => array:3 [ "nombre" => "Saboura" "apellidos" => "Nikpour" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "af0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "af0020" ] ] ] 4 => array:3 [ "nombre" => "Alireza" "apellidos" => "Fereidouni" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "af0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "af0020" ] ] ] 5 => array:4 [ "nombre" => "Mohammad" "apellidos" => "Fereidouni" "email" => array:1 [ 0 => "Dr.m.fereidouni@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "af0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cr0005" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "fn0005" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran" "etiqueta" => "a" "identificador" => "af0005" ] 1 => array:3 [ "entidad" => "Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran" "etiqueta" => "b" "identificador" => "af0010" ] 2 => array:3 [ "entidad" => "Immunology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran" "etiqueta" => "c" "identificador" => "af0015" ] 3 => array:3 [ "entidad" => "Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran" "etiqueta" => "d" "identificador" => "af0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cr0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding authors." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Análisis del nivel de anticuerpos séricos protectores tras la tercera dosis de diferentes vacunas contra la COVID-19" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "f0010" "etiqueta" => "Fig 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1500 "Ancho" => 1382 "Tamanyo" => 106361 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0010" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0010" class="elsevierStyleSimplePara elsevierViewall">The comparison of vaccine efficacy in different platforms after second and third dose. The data are reported as the mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SD of at least 3 independent experiments. * indicates a statistically significant difference compared to the sputnik V d2 group and Pas d3.* indicates a statistically significant difference compared to the vaxzevria group and Pas d3.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="s0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0025">Introduction</span><p id="p0005" class="elsevierStylePara elsevierViewall">A new coronavirus (SARS-CoV-2), causing COVID-19 (coronavirus disease 2019), is a member of the family Coronaviridae. Also, this family includes severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome coronaviruses,<a class="elsevierStyleCrossRef" href="#bb0005"><span class="elsevierStyleSup">1</span></a> which contain several non-structural and structural proteins encoded by their genomes, including spike (S), nucleocapsid (N), membrane (M), and envelope (E).<a class="elsevierStyleCrossRef" href="#bb0010"><span class="elsevierStyleSup">2</span></a> COVID-19 vaccine candidates are conceptualized with the aim of administering viral antigens or viral gene sequences to stimulate neutralizing antibodies against the viral spike protein (S), followed by blocking virus uptake by the ACE2 receptor.<a class="elsevierStyleCrossRef" href="#bb0015"><span class="elsevierStyleSup">3</span></a> In the battle against SARS-CoV-2 infection, a vaccine-development effort with unprecedented speed began on January 11, 2020, in response to the availability of the genome sequence.<a class="elsevierStyleCrossRef" href="#bb0020"><span class="elsevierStyleSup">4</span></a> Despite all this, new COVID-19 cases caused by the highly transmissible delta variant have exacerbated the public health crisis worldwide, raising the question about the need and timing of the administration of booster doses for vaccinated populations.<a class="elsevierStyleCrossRef" href="#bb0025"><span class="elsevierStyleSup">5</span></a> Although it is appealing to increase immunity among COVID-19 vaccine recipients to reduce the number of infected cases, any such decision should be evidence-based and weigh both the risks and benefits for individuals and society. Needless to say, COVID-19 vaccines still have significant effectiveness against severe variants, including delta 1.<a class="elsevierStyleCrossRef" href="#bb0030"><span class="elsevierStyleSup">6</span></a> Due to the potential confounding and selective reports, most observational studies supporting this conclusion are preliminary and challenging to precisely interpret the results. Therefore, a systematic and public examination of the evolving data would be required to decide about boosting based on reliable science rather than merely political considerations. However, the booster doses could still decrease the medium-term risk of severe disease in the case of having a beneficial long-term effect on unvaccinated populations rather than already vaccinated people.<a class="elsevierStyleCrossRef" href="#bb0035"><span class="elsevierStyleSup">7</span></a> Individuals who received a one- or two-dose series of each vaccine for the primary vaccination might not have received adequate protection, such as those who received vaccines with low efficacy or those who are immunocompromised.<a class="elsevierStyleCrossRef" href="#bb0040"><span class="elsevierStyleSup">8</span></a> Apart from that, an additional dose of the same vaccine or a different vaccine that may complement the primary immune response would be more beneficial to immunocompromised individuals.<a class="elsevierStyleCrossRef" href="#bb0045"><span class="elsevierStyleSup">9</span></a> In the general population, booster vaccinations are sometimes needed due to either reduced immunity to the original vaccine or the insufficient immune response of original vaccine antigens against circulating evolved viruses.<a class="elsevierStyleCrossRef" href="#bb0050"><span class="elsevierStyleSup">10</span></a></p><p id="p0010" class="elsevierStylePara elsevierViewall">Clearly, the benefits of the primary COVID-19 vaccination far outweigh the risks. Nevertheless, the risks associated with too early and too frequent boosters should be considered, especially when vaccines have immune-mediated effects like myocarditis, which is more commonly associated with the second dose of some mRNA vaccines.<a class="elsevierStyleCrossRef" href="#bb0055"><span class="elsevierStyleSup">11</span></a> Since a significant adverse reaction caused by unnecessary boosters may affect COVID-19 vaccine acceptance, widespread boosting should only be undertaken when needed.<a class="elsevierStyleCrossRef" href="#bb0060"><span class="elsevierStyleSup">12</span></a> Randomized trial studies have consistently demonstrated the high initial efficacy of several vaccines.<a class="elsevierStyleCrossRef" href="#bb0065"><span class="elsevierStyleSup">13</span></a> In contrast, observational studies have shown a lower initial efficacy and/or a less-durable efficacy of vaccines.<a class="elsevierStyleCrossRef" href="#bb0070"><span class="elsevierStyleSup">14</span></a> This study aimed to detect the difference between neutralizing anti-RBD immunoglobulin G between a third and second dose of various vaccine platforms.</p></span><span id="s0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0030">Materials and methods</span><span id="s0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0035">Design of study</span><p id="p0015" class="elsevierStylePara elsevierViewall">In our recent study conducted from May to August 2021, individuals associated with Birjand University of Medical Sciences, Birjand, Iran comprising healthcare workers, students, and administrative staff, who expressed interest in receiving the COVID-19 vaccine were invited to participate. Participants were required to provide 5 ml of venous blood before receiving the first dose of the vaccine and 2 weeks after the second dose. Additionally, participants were asked to complete an online questionnaire covering demographic data, history of previous COVID-19 infection, and details about the date and type of received vaccines.<a class="elsevierStyleCrossRef" href="#bb0075"><span class="elsevierStyleSup">15</span></a> In the following our previous research, this study has been done among eligible cases who had received the third dose of vaccine in the last 2–4 weeks. In this study (the interval between the second dose and the booster dose was 4–6 month), 30 people were selected who participated in the previous study included those who desired to take the COVID-19 vaccine, such as students, employees, and administrative staff. The inclusion criteria for this study were injections of third doses of one of the vaccines Vaxzevria, Covilo, and PastoCovac Plus and participated in our previous study. Exclusion criteria were: unwillingness to donate blood on time, and positive COVID-19 test during the study period. Then, 5 ml of venous blood were collected from each participant 2 weeks after receiving the third dose of vaccine (Vaxzevria, Covilo, and PastoCovac Plus) To separate the serum, the samples were centrifuged at 2000 rpm for 10 min and then stored at −<span class="elsevierStyleHsp" style=""></span>20 °C until further analysis. Then, to evaluate the level of anti-SARS-CoV-2 neutralizing antibodies, a commercial IgG antibody detection kit against SARS-CoV-2 RBD (ChemoBind®) was used. This kit can detect RBD-ACE2 reaction inhibitory antibodies by indirect ELISA. Thus, the plate wells were coated with RBD antigen (spike S). Finally, based on indirect ELISA and light absorption for each sample, the immunological status ratio (ISR) was measured and based on the ISR value, the samples were divided into 3 categories: positive (ISR ≥<span class="elsevierStyleHsp" style=""></span>1.1), negative (ISR ≤<span class="elsevierStyleHsp" style=""></span>0.8), and the need for re-testing (0.8–1.1).<elsevierMultimedia ident="fo0005"></elsevierMultimedia></p></span><span id="s0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0040">Ethical approval</span><p id="p0020" class="elsevierStylePara elsevierViewall">The Ethics Committee of the Birjand University of Medical University approved this study (IR.BUMS.REC.1400.027). The informed consent was obtained from all participants.</p></span></span><span id="s0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0045">Statistical analysis</span><p id="p0025" class="elsevierStylePara elsevierViewall">SPSS software version 22.0 (SPSS Inc. Chicago, IL) was used to analyze the data. Statistical analysis was done using Student's <span class="elsevierStyleItalic">t</span>-test and Chi-square tests at a significance value of <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.05. Analysis of more than 2 groups was completed by one-way ANOVA and Tukey's post-hoc test with a <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.05.</p></span><span id="s0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0050">Results</span><span id="s0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0055">Demographic characteristics</span><p id="p0030" class="elsevierStylePara elsevierViewall">In total, 30 participants were included (mean age of 35.62<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>8.72 years, range of 21–53 years, Male/Female ratio:). Details of the demographic information and type of vaccines were summarized in (<a class="elsevierStyleCrossRef" href="#t0005">Table 1</a>).</p><elsevierMultimedia ident="t0005"></elsevierMultimedia></span><span id="s0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0060">COVID-19 vaccine efficiency</span><span id="s0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0065">Comparison of the vaccine effectiveness after third dose</span><p id="p0035" class="elsevierStylePara elsevierViewall">The positive frequency of RBD protein antibody 2 weeks after the third dose of vaccines is shown in <a class="elsevierStyleCrossRef" href="#f0005">Fig. 1</a>. As it is demonstrated in <a class="elsevierStyleCrossRef" href="#f0010">Fig. 2</a>, all vaccines showed significantly higher efficacy in the third dose than in the second dose. A comparison of vaccine efficacy showed that there was significant difference in immunogenicity between the 2 doses; however, participants who received Vaxzevria and PastoCovac Plus in the third dose significantly had a better immunogenicity than the second dose, participants who received Vaxzevria in second dose and PastoCovac Plus in third dose had more immunogenicity (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.05) (<a class="elsevierStyleCrossRef" href="#f0010">Fig. 2</a>).</p><elsevierMultimedia ident="f0005"></elsevierMultimedia><elsevierMultimedia ident="f0010"></elsevierMultimedia></span></span></span><span id="s0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0070">Discussion</span><p id="p0040" class="elsevierStylePara elsevierViewall">At present, vaccination provides the best protection against COVID-19 infection. Observations indicate that humoral immunity against SARS-CoV-2 infection appears to be reduced in the months after vaccination, especially in the elderly and those with immunosuppression.<a class="elsevierStyleCrossRefs" href="#bb0080"><span class="elsevierStyleSup">16–18</span></a> In the present study, the efficacy between the second and third dose of Vaxzevria A, Covilo, and PastoCovac Plus was studied in people with the age of 21–53 years who received the vaccine 2–4 weeks after the second dose. In accordance with others, the results of the current research showed that titers of neutralization geometric mean against the covid increased after a booster dose administered approximately 2–4 weeks after the second dose, Therefore, the greatest effectiveness of the vaccine is observed after 2–4 weeks after the injection of the booster dose of the vaccine.<a class="elsevierStyleCrossRef" href="#bb0045"><span class="elsevierStyleSup">9</span></a> COVID-19 booster vaccinations have been implemented in some countries based on the above-mentioned data as well as immunological and safety results from the pivotal trials.<a class="elsevierStyleCrossRef" href="#bb0095"><span class="elsevierStyleSup">19</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bb0100"><span class="elsevierStyleSup">20</span></a> According to our results, PastoCovac Plus vaccines are more effective than Covilo and Vaxzevria vaccines in the third dose probably because of different vaccines platforms.<a class="elsevierStyleCrossRef" href="#bb0085"><span class="elsevierStyleSup">17</span></a> In a more detail, live viral carriers are used in the Vaxzevria vaccines platform.<a class="elsevierStyleCrossRef" href="#bb0105"><span class="elsevierStyleSup">21</span></a> While, in the Covilo’s vaccine inactive viruses are applied that have a minor effects on the immune system.<a class="elsevierStyleCrossRef" href="#bb0110"><span class="elsevierStyleSup">22</span></a> Also, PastoCovac Plus is a conjugate vaccine. Studies showed that Vaxzevria and Sputnik V vaccines could produce about 90% immunogenicity 30.31. According to most studies, the effectiveness of Covilo vaccines is near 70%.<a class="elsevierStyleCrossRef" href="#bb0115"><span class="elsevierStyleSup">23</span></a> Although, no studies are available about the efficacy of the PastoCovac Plus vaccine, according to our data, participants who received Vaxzevria in the second dose and PastoCovac Plus in the third dose showed the higher titers of antibodies. Our data showed that a booster dose administered approximately 2–4 weeks after the third dose increased the geometric mean titers against the delta variant. The pivotal trial results and immunological and safety findings for a booster dose have led to some countries conducting booster vaccinations with COVID-19. Based, it is crucial to use published data from prospective and randomized trials regarding booster doses’ safety, immunogenicity, and effectiveness as soon as possible.<a class="elsevierStyleCrossRef" href="#bb0120"><span class="elsevierStyleSup">24</span></a></p><p id="p0045" class="elsevierStylePara elsevierViewall">Regarding the effectiveness of boosters in real-world situations, a trial involving elderly Israeli adults showed that the third dose of BNT162b2 vaccine administered at least 5 months after the second dose resulted in a lower incidence of SARS-CoV-2 infection and severe form of the COVID-19.<a class="elsevierStyleCrossRef" href="#bb0095"><span class="elsevierStyleSup">19</span></a> Similar to our findings, several studies from the UK, Germany, and Spain showed that injection various vaccine platforms resulted in a higher antibody response than receiving 2 doses of the viral vector vaccine. To “boost” the immune system, administration of an Oxford-Vaxzevria viral vector vaccine and then a Pfizer-BioNTech mRNA vaccine could better stimulate different parts of the immune system, resulting in a more robust immune response than a viral vector vaccine alone. According to the results of this study, a third dose of the vaccine should be given to persons aged ≥<span class="elsevierStyleHsp" style=""></span>20 years to provide an increased level of protection against COVID-19. Especially, participants who received a Sputnik-V and Vaxzevria in the second dose and PastoCovac Plus in the third dose showed a more effective immune response against the virus.</p></span><span id="s0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0075">Author contributions</span><p id="p0050" class="elsevierStylePara elsevierViewall">Study concept and design: A.M.</p><p id="p0055" class="elsevierStylePara elsevierViewall">Acquisition of data: M. R.</p><p id="p0060" class="elsevierStylePara elsevierViewall">Analysis and interpretation of data: S. A. E.</p><p id="p0065" class="elsevierStylePara elsevierViewall">Drafting of the manuscript: S.N.</p><p id="p0070" class="elsevierStylePara elsevierViewall">Critical revision of the manuscript for important intellectual content: A.M.</p><p id="p0075" class="elsevierStylePara elsevierViewall">Statistical analysis: A.F.</p><p id="p0080" class="elsevierStylePara elsevierViewall">Administrative, technical, and material support: M.F</p></span><span id="s0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0080">Ethics</span><p id="p0085" class="elsevierStylePara elsevierViewall">All ethical standards approved by the ethics committee of the Birjand University of Medical Sciences (IR. bums.1401.162)</p></span><span id="s0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0085">Funding</span><p id="p0090" class="elsevierStylePara elsevierViewall">This work was supported by <span class="elsevierStyleGrantSponsor" id="gts0005">Birjand University of medical sciences</span> (<span class="elsevierStyleGrantNumber" refid="gts0005">5878</span>).</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:14 [ 0 => array:3 [ "identificador" => "xres2141551" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "as0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1818109" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres2141550" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "as0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1818110" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "s0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "s0010" "titulo" => "Materials and methods" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "s0015" "titulo" => "Design of study" ] 1 => array:2 [ "identificador" => "s0020" "titulo" => "Ethical approval" ] ] ] 6 => array:2 [ "identificador" => "s0025" "titulo" => "Statistical analysis" ] 7 => array:3 [ "identificador" => "s0030" "titulo" => "Results" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "s0035" "titulo" => "Demographic characteristics" ] 1 => array:3 [ "identificador" => "s0040" "titulo" => "COVID-19 vaccine efficiency" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "s0045" "titulo" => "Comparison of the vaccine effectiveness after third dose" ] ] ] ] ] 8 => array:2 [ "identificador" => "s0050" "titulo" => "Discussion" ] 9 => array:2 [ "identificador" => "s0055" "titulo" => "Author contributions" ] 10 => array:2 [ "identificador" => "s0060" "titulo" => "Ethics" ] 11 => array:2 [ "identificador" => "s0065" "titulo" => "Funding" ] 12 => array:2 [ "identificador" => "xack743300" "titulo" => "Acknowledgments" ] 13 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2023-12-11" "fechaAceptado" => "2024-02-15" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1818109" "palabras" => array:6 [ 0 => "SARS-CoV-2" 1 => "Vaxzevria" 2 => "PastoCovac Plus" 3 => "COVID-19 vaccines" 4 => "Immunity" 5 => "Booster vaccination" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1818110" "palabras" => array:6 [ 0 => "SARS-CoV-2" 1 => "Vaxzevria" 2 => "PastoCovac Plus" 3 => "vacunas contra la COVID-19" 4 => "Inmunidad" 5 => "vacunación de refuerzo" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="as0005" class="elsevierStyleSection elsevierViewall"><p id="sp0025" class="elsevierStyleSimplePara elsevierViewall">A new coronavirus (SARS-CoV-2), causing COVID-19 (coronavirus disease 2019), is a member of the Coronaviridae family. The benefits of the primary COVID-19 vaccination far outweigh the risks. Nevertheless, the risks associated with too early and too frequent boosters should be considered, especially when vaccines have immune-mediated effects like myocarditis, which is more commonly associated with the second dose of some mRNA vaccines. Booster vaccinations against SARS-CoV-2 are needed because of either reduced immunity to the original vaccine or evolved viruses producing immunity to the initial vaccine antigens. So, the aim of this study was to detect the difference in neutralizing anti-RBD antibodies between the third and second doses of COVID-19 vaccines. A study was performed among 29 eligible participants in Birjand (Iran). Blood samples were taken from all participants 2–4 weeks after the third dose. In the next step, humoral responses were assessed with a kit detecting neutralization of SARS-CoV-2. SPSS software version 22.0 (SPSS Inc., Chicago, IL) was used to analyze the data. The mean age of cases was 35.62<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>8.72 years, with a range of 21–53 years. The obtained results showed that all vaccines significantly had a higher efficacy in the third dose than the second. Participants who received Vaxzevria in the second dose and PastoCovac Plus in the third dose had more immunogenicity. According to the results of this study, a third dose of the vaccine should be given to persons aged ≥<span class="elsevierStyleHsp" style=""></span>20 years to provide an increased level of protection against COVID-19. Especially, participants who received Sputnik-V and Vaxzevria in the second dose and PastoCovac Plus in the third dose showed a more effective immune response against the virus.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="as0010" class="elsevierStyleSection elsevierViewall"><p id="sp0030" class="elsevierStyleSimplePara elsevierViewall">Un nuevo coronavirus (SARS-CoV-2), causante de la COVID-19 (enfermedad por coronavirus de 2019), se ha unido a la familia Coronaviridae. Los beneficios de la vacunación contra la COVID-19 primaria superaron con creces los riesgos. Sin embargo, deberán considerarse los riesgos asociados a los refuerzos demasiado tempranos y frecuentes, y en especial cuando las vacunas tienen efectos inmunomediados tales como la miocarditis, que está más comúnmente asociada a la segunda dosis de algunas vacunas ARNm. Las vacunas de refuerzo contra la SARS-CoV-2 son necesarias, debido a la inmunidad reducida de la vacuna original, o bien a la evolución de los virus que producen inmunidad frente a los antígenos de la vacuna inicial. Por ello, el objetivo de este estudio fue detectar la diferencia en términos de neutralización de los anticuerpos anti-RBD entre la tercera y segunda dosis de las vacunas frente a la COVID-19. Se realizó un estudio con 29 participantes elegibles en Birjand (Irán). Se tomaron muestras de sangre de todos los participantes, transcurridas de 2 a 4 semanas de la tercera dosis. En la siguiente etapa se evaluaron las respuestas humorales con un kit para detectar la neutralización de SARS-CoV-2. Se utilizó el software SPSS versión 22.0 (SPSS Inc., Chicago, IL, EEUU) para analizar los datos. La edad media de los casos fue de 35,62 ± 8,72 años, con rango de 21 a 53 años. Los resultados obtenidos reflejaron que todas las vacunas tenían una eficacia significativamente mayor en la tercera dosis, en comparación con la segunda. Los participantes que recibieron Vaxzevria en la segunda dosis, y PastoCovac Plus en la tercera, tuvieron mayor inmunogenicidad. De acuerdo con los resultados de este estudio, deberá administrarse una dosis de la vacuna a las personas ≥<span class="elsevierStyleHsp" style=""></span>20 años, para aportar un nivel incrementado de protección frente a la COVID-19. En especial, los participantes que recibieron Sputnik-V y Vaxzevria en la segunda dosis, y PastoCovac Plus en la tercera, reflejaron una respuesta inmunitaria más efectiva frente al virus.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:3 [ "etiqueta" => "1" "nota" => "<p class="elsevierStyleNotepara" id="np0005">These authors contributed equally to this work.</p>" "identificador" => "fn0005" ] ] "multimedia" => array:4 [ 0 => array:8 [ "identificador" => "f0005" "etiqueta" => "Fig 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1208 "Ancho" => 1382 "Tamanyo" => 60383 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0005" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0005" class="elsevierStyleSimplePara elsevierViewall">Titer of antibody after the second and third dose of COVID-19 vaccines.</p>" ] ] 1 => array:8 [ "identificador" => "f0010" "etiqueta" => "Fig 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1500 "Ancho" => 1382 "Tamanyo" => 106361 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0010" "detalle" => "Fig " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="sp0010" class="elsevierStyleSimplePara elsevierViewall">The comparison of vaccine efficacy in different platforms after second and third dose. The data are reported as the mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SD of at least 3 independent experiments. * indicates a statistically significant difference compared to the sputnik V d2 group and Pas d3.* indicates a statistically significant difference compared to the vaxzevria group and Pas d3.</p>" ] ] 2 => array:8 [ "identificador" => "t0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "al0015" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="sp0020" class="elsevierStyleSimplePara elsevierViewall">*One-way ANOVA was used at a significance level of <<span class="elsevierStyleHsp" style=""></span>.05.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Variable \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Vaxzevria \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pasto covac plus \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Covilo \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Sputunik</span> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p-value</span> \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Type of vaccine Dose 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 (58.7%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (24%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (17.3%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Type of vaccine Dose 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13(44.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4(13.7%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12(41.37) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">.01 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>40 years (58.6%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 (50%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (50%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (60%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>40 years (41.4%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 (50%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (50%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (40%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sex \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (24.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (13.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2(6.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (34.5%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3(10.34%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3(10.34%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3530323.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="sp0015" class="elsevierStyleSimplePara elsevierViewall">A statistical analysis of the demographic characteristics of vaccine recipients.</p>" ] ] 3 => array:5 [ "identificador" => "fo0005" "tipo" => "MULTIMEDIAFORMULA" "mostrarFloat" => false "mostrarDisplay" => true "Formula" => array:5 [ "Matematica" => "IRS=ODof the clinical sampleCutoff=0.22+ODof Negative control." "Fichero" => "STRIPIN_si1.jpeg" "Tamanyo" => 180 "Alto" => 20 "Ancho" => 205 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0005" "bibliografiaReferencia" => array:24 [ 0 => array:3 [ "identificador" => "bb0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A comprehensive review of COVID-19 characteristics" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "H. Esakandari" 1 => "M. Nabi-Afjadi" 2 => "J. Fakkari-Afjadi" 3 => "N. Farahmandian" 4 => "S.-M. Miresmaeili" 5 => "E. Bahreini" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Biol Proc Online" "fecha" => "2020" "volumen" => "22" "numero" => "1" "paginaInicial" => "1" "paginaFinal" => "10" "itemHostRev" => array:3 [ "pii" => "S0140673623011911" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bb0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.Y. Lee" 1 => "J.-B. Cazier" 2 => "V. Angelis" 3 => "R. Arnold" 4 => "V. Bisht" 5 => "N.A. Campton" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "The Lancet." "fecha" => "2020" "volumen" => "395" "numero" => "10241" "paginaInicial" => "1919" "paginaFinal" => "1926" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bb0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "N.C. Kyriakidis" 1 => "A. López-Cortés" 2 => "E.V. González" 3 => "A.B. Grimaldos" 4 => "E.O. Prado" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41541-020-00265-5" "Revista" => array:7 [ "tituloSerie" => "npj Vaccines" "fecha" => "2021" "volumen" => "6" "numero" => "1" "paginaInicial" => "1" "paginaFinal" => "17" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33398010" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bb0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A novel coronavirus from patients with pneumonia in China, 2019" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Zhu" 1 => "D. Zhang" 2 => "W. Wang" 3 => "X. Li" 4 => "B. Yang" 5 => "J. Song" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2001017" "Revista" => array:7 [ "tituloSerie" => "New Engl J Med" "fecha" => "2020" "volumen" => "382" "numero" => "8" "paginaInicial" => "727" "paginaFinal" => "733" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31978945" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bb0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F.-C. Zhu" 1 => "Y.-H. Li" 2 => "X.-H. Guan" 3 => "L.-H. Hou" 4 => "W.-J. Wang" 5 => "J.-X. Li" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "The Lancet." "fecha" => "2020" "volumen" => "395" "numero" => "10240" "paginaInicial" => "1845" "paginaFinal" => "1854" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bb0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F.-C. Zhu" 1 => "X.-H. Guan" 2 => "Y.-H. Li" 3 => "J.-Y. Huang" 4 => "T. Jiang" 5 => "L.-H. Hou" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "The Lancet." "fecha" => "2020" "volumen" => "396" "numero" => "10249" "paginaInicial" => "479" "paginaFinal" => "488" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bb0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Wu" 1 => "A. Choi" 2 => "M. Koch" 3 => "L. Ma" 4 => "A. Hill" 5 => "N. Nunna" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "MedRxiv" "fecha" => "2021 May" "numero" => "6" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bb0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18–59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Pan" 1 => "Q. Wu" 2 => "G. Zeng" 3 => "J. Yang" 4 => "D. Jiang" 5 => "X. Deng" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "MedRxiv" "fecha" => "2021 Jul" "volumen" => "25" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bb0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Considerations in boosting COVID-19 vaccine immune responses" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.R. Krause" 1 => "T.R. Fleming" 2 => "R. Peto" 3 => "I.M. Longini" 4 => "J.P. Figueroa" 5 => "J.A. Sterne" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "The Lancet" "fecha" => "2021" "volumen" => "398" "numero" => "10308" "paginaInicial" => "1377" "paginaFinal" => "1380" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bb0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Homologous and heterologous Covid-19 booster vaccinations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:11 [ 0 => "R.L. Atmar" 1 => "K.E. Lyke" 2 => "M.E. Deming" 3 => "L.A. Jackson" 4 => "A.R. Branche" 5 => "H.M. El Sahly" 6 => "C.A. Rostad" 7 => "J.M. Martin" 8 => "C. Johnston" 9 => "R.E. Rupp" 10 => "M.J. Mulligan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2116414" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2022 Mar 17" "volumen" => "386" "numero" => "11" "paginaInicial" => "1046" "paginaFinal" => "1057" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35081293" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bb0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 Vaccination: Evidence of Waning Immunity Is Overstated" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. Scott" 1 => "A. Richterman" 2 => "M. Cevik" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2021" "editorial" => "British Medical Journal Publishing Group" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bb0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "BNT162b2 vaccine booster and mortality due to COVID-19" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Arbel" 1 => "A. Hammerman" 2 => "R. Sergienko" 3 => "M. Friger" 4 => "A. Peretz" 5 => "D. Netzer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2115624" "Revista" => array:7 [ "tituloSerie" => "New Engl J Med" "fecha" => "2021" "volumen" => "385" "numero" => "26" "paginaInicial" => "2413" "paginaFinal" => "2420" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34879190" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bb0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26. COV2. S COVID-19 vaccines" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Naranbhai" 1 => "W.F. Garcia-Beltran" 2 => "C.C. Chang" 3 => "C. Berrios Mairena" 4 => "J.C. Thierauf" 5 => "G. Kirkpatrick" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/infdis/jiab593" "Revista" => array:7 [ "tituloSerie" => "J Infect Dis" "fecha" => "2022" "volumen" => "225" "numero" => "7" "paginaInicial" => "1141" "paginaFinal" => "1150" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34888672" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bb0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Fendler" 1 => "E.G. de Vries" 2 => "C.H. GeurtsvanKessel" 3 => "J.B. Haanen" 4 => "B. Wörmann" 5 => "S. Turajlic" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41571-022-00610-8" "Revista" => array:7 [ "tituloSerie" => "Nat Rev Clin Oncol" "fecha" => "2022" "volumen" => "19" "numero" => "6" "paginaInicial" => "385" "paginaFinal" => "401" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35277694" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bb0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of COVID-19 vaccines (Sputnik V, VAXZEVRIA, and Covaxin) side effects among healthcare workers in Birjand city" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "H. Zare" 1 => "H. Rezapour" 2 => "S. Mahmoodzadeh" 3 => "M. Fereidouni" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Iran Int Immunopharmacol" "fecha" => "2021" "volumen" => "101" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bb0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Waning immunity after the BNT162b2 vaccine in Israel" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Goldberg" 1 => "M. Mandel" 2 => "Y.M. Bar-On" 3 => "O. Bodenheimer" 4 => "L. Freedman" 5 => "E.J. Haas" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "New Engl J Med." "fecha" => "2021" "volumen" => "385" "numero" => "24" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bb0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.G. Levin" 1 => "Y. Lustig" 2 => "C. Cohen" 3 => "R. Fluss" 4 => "V. Indenbaum" 5 => "S. Amit" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "New Engl J Med." "fecha" => "2021" "volumen" => "385" "numero" => "24" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bb0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New COVID-19 cases and hospitalizations among adults, by vaccination status—New York, May 3–July 25, 2021" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.S. Rosenberg" 1 => "D.R. Holtgrave" 2 => "V. Dorabawila" 3 => "M. Conroy" 4 => "D. Greene" 5 => "E. Lutterloh" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Morb Mortal Wkly Rep" "fecha" => "2021" "volumen" => "70" "numero" => "37" "paginaInicial" => "1306" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bb0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "BNT162b2 vaccine booster dose protection: A nationwide study from Israel" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:11 [ 0 => "Y.M. Bar-On" 1 => "Y. Goldberg" 2 => "M. Mandel" 3 => "O. Bodenheimer" 4 => "L. Freedman" 5 => "N. Kalkstein" 6 => "B. Mizrahi" 7 => "S. Alroy-Preis" 8 => "N. Ash" 9 => "R. Milo" 10 => "A. Huppert" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "MedRxiv." "fecha" => "2021 Aug" "volumen" => "31" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bb0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.D. Moreira Jr." 1 => "N. Kitchin" 2 => "X. Xu" 3 => "S.S. Dychter" 4 => "S. Lockhart" 5 => "A. Gurtman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2200674" "Revista" => array:7 [ "tituloSerie" => "New Engl J Med." "fecha" => "2022" "volumen" => "386" "numero" => "20" "paginaInicial" => "1910" "paginaFinal" => "1921" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35320659" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bb0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:11 [ 0 => "N. Andrews" 1 => "J. Stowe" 2 => "F. Kirsebom" 3 => "S. Toffa" 4 => "T. Rickeard" 5 => "E. Gallagher" 6 => "C. Gower" 7 => "M. Kall" 8 => "N. Groves" 9 => "A.M. O’Connell" 10 => "D. Simons" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "MedRxiv." "fecha" => "2021 Dec" "volumen" => "14" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bb0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Do Vaccines Protect Against Long COVID? What the Data Say" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "H. Ledford" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2021" "editorial" => "Nature Publishing Group" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bb0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: a prospective multicenter study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.C. Maltezou" 1 => "P. Panagopoulos" 2 => "F. Sourri" 3 => "T.V. Giannouchos" 4 => "V. Raftopoulos" 5 => "M.N. Gamaletsou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2021.10.054" "Revista" => array:7 [ "tituloSerie" => "Vaccine" "fecha" => "2021" "volumen" => "39" "numero" => "48" "paginaInicial" => "7021" "paginaFinal" => "7027" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34740473" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bb0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Development and evaluation of anti-inflammatory oleogels of Bosewellia serrata (GUGUL) and Curcuma longa (TURMERIC)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B.K. Shrikhande" 1 => "D.C. Goupale" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Indian Drugs" "fecha" => "2001" "volumen" => "38" "numero" => "12" "paginaInicial" => "613" "paginaFinal" => "616" ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack743300" "titulo" => "Acknowledgments" "texto" => "<p id="p0100" class="elsevierStylePara elsevierViewall">This work was financially supported by <span class="elsevierStyleGrantSponsor" id="gts0010">Birjand University of Medical Sciences. Birjand. Iran</span>.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/15769887/0000002500000002/v2_202405080710/S1576988724000219/v2_202405080710/en/main.assets" "Apartado" => array:4 [ "identificador" => "17855" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Originales" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15769887/0000002500000002/v2_202405080710/S1576988724000219/v2_202405080710/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988724000219?idApp=UINPBA00004N" ]
